Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and
to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
Naloxegol may relieve some of the side effects of opioid pain medication and fight off future
growth in the cancer.